Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2016 October;68(5) > Minerva Ginecologica 2016 October;68(5):517-35

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints
Cite this article as

MINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  HEREDITARY GENITAL AND BREAST CANCER


Minerva Ginecologica 2016 October;68(5):517-35

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Pharmacoprevention for hereditary breast and ovarian cancer

Massimiliano CAZZANIGA, Bernardo BONANNI

Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy


PDF  


Hereditary breast and ovarian cancer (HBOC) syndrome is an important women’s health condition characterized by an increased susceptibility to the development of cancer, in particular breast and ovarian neoplasms, and is caused by an inherited germline genetic mutation in one or both tumor suppressor genes named BRCA1 and BRCA2. This monographic issue provides an update on our knowledge of this syndrome with particular emphasis on the risk reduction strategies through a pharmacopreventive approach.

top of page

Publication History

Cite this article as

Cazzaniga M, Bonanni B. Pharmacoprevention for hereditary breast and ovarian cancer. Minerva Ginecol 2016 October;68(5):517-35. 

Corresponding author e-mail

massimiliano.cazzaniga@ieo.it